Febuxostat pretreatment attenuates myocardial ischemia/reperfusion injury via mitochondrial apoptosis

被引:58
|
作者
Wang, Shulin [1 ]
Li, Yunpeng [1 ]
Song, Xudong [1 ]
Wang, Xianbao [1 ]
Zhao, Cong [1 ]
Chen, Aihua [1 ]
Yang, Pingzhen [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Cardiol, Guangzhou 510280, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Febuxostat; Myocardial ischemia/reperfusion injury; Mitochondrial damage; Apoptosis; ISCHEMIA-REPERFUSION INJURY; OXIDATIVE STRESS; CELL-DEATH; ALLOPURINOL; INHIBITION; MECHANISMS; INFARCTION; PATHWAYS; OVERLOAD; COPPER;
D O I
10.1186/s12967-015-0578-x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Febuxostat is a selective inhibitor of xanthine oxidase (XO). XO is a critical source of reactive oxygen species (ROS) during myocardial ischemia/reperfusion (I/R) injury. Inhibition of XO is therapeutically effective in I/R injury. Evidence suggests that febuxostat exerts antioxidant effects by directly scavenging ROS. The present study was performed to investigate the effects of febuxostat on myocardial I/R injury and its underlying mechanisms. Methods: We utilized an in vivo mouse model of myocardial I/R injury and an in vitro neonatal rat cardiomyocyte (NRC) model of hypoxia/reoxygenation (H/R) injury. Mice were randomized into five groups: Sham, I/R (I/R + Vehicle), I/R + FEB (I/R + febuxostat), AL + I/R (I/R + allopurinol) and FEB (febuxostat), respectively. The I/R + FEB mice were pretreated with febuxostat (5 mg/kg; i.p.) 24 and 1 h prior to I/R. NRCs received febuxostat (1 and 10 mu M) at 24 and 1 h before exposure to hypoxia for 3 h followed by reoxygenation for 3 h. Cardiac function, myocardial infarct size, serum levels of creatine kinase (CK) and lactate dehydrogenase (LDH), and myocardial apoptotic index (AI) were measured in order to ascertain the effects of febuxostat on myocardial I/R injury. Hypoxia/reperfusion (H/R) injury in NRCs was examined using MTT, LDH leakage assay and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The underlying mechanisms were determined by measuring ROS production, mitochondrial membrane potential (Delta Psi m), and expression of cytochrome c, cleaved caspases as well as Bcl-2 protein levels. Results: Myocardial I/R led to an elevation in the myocardial infarct size, serum levels of CK and LDH, cell death and AI. Furthermore, I/R reduced cardiac function. These changes were significantly attenuated by pretreatment with febuxostat and allopurinol, especially by febuxostat. Febuxostat also protected the mitochondrial structure following myocardial I/R, inhibited H/R-induced ROS generation, stabilized the Delta Psi m, alleviated cytosolic translocation of mitochondrial cytochrome C, inhibited activation of caspase-3 and -9, upregulated antiapoptotic proteins and downregulated proapoptotic proteins. Conclusions: This study revealed that febuxostat pretreatment mediates the cardioprotective effects against I/R and H/R injury by inhibiting mitochondrial-dependent apoptosis.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Paricalcitol pretreatment attenuates apoptosis and inflammation in renal ischemia-reperfusion injury via EP4 pathway
    Hwang, Hyeon Seok
    Hong, Yu Ah
    Chang, Yoon Kyung
    Kim, Suk Young
    TRANSPLANTATION, 2016, 100 (07) : S605 - S605
  • [22] Withaferin a Attenuates Myocardial Ischemia/Reperfusion Injury via Mitochondrial Death Cascade Blockade in an AMPK Dependent Manner
    Guo, Rui
    Lau, Wayne Bond
    Yan, Zheyi
    Gan, Lu
    Yan, Wenjun
    Zhao, Dajun
    Xie, Dina
    Ma, Xinliang
    Gao, Erhe
    Wang, Yajing
    CIRCULATION, 2017, 136
  • [23] Mitochondrial Transplantation in Myocardial Ischemia and Reperfusion Injury
    Shin, Borami
    Cowan, Douglas B.
    Emani, Sitaram M.
    del Nido, Pedro J.
    McCully, James D.
    MITOCHONDRIAL DYNAMICS IN CARDIOVASCULAR MEDICINE, 2017, 982 : 595 - 619
  • [24] Inhibition of phosphodiesterase 4 attenuates myocardial ischemia/reperfusion injury by inhibiting cardiomyocytes apoptosis
    Kwak, Hyun Jeong
    ADVANCES IN TRADITIONAL MEDICINE, 2024, 24 (04) : 1087 - 1092
  • [25] Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function
    Elrod, John W.
    Calvert, John W.
    Morrison, Joanna
    Doeller, Jeannette E.
    Kraus, David W.
    Tao, Ling
    Jiao, Xiangying
    Scalia, Rosario
    Kiss, Levente
    Szabo, Csaba
    Kimura, Hideo
    Chow, Chi-Wing
    Lefer, David J.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (39) : 15560 - 15565
  • [26] Inhibition of cathepsin S attenuates myocardial ischemia/reperfusion injury by suppressing inflammation and apoptosis
    Peng, Ke
    Liu, Hong
    Yan, Bin
    Meng, Xiao-Wen
    Song, Shao-Yong
    Ji, Fu-Hai
    Xia, Zhengyuan
    JOURNAL OF CELLULAR PHYSIOLOGY, 2021, 236 (02) : 1309 - 1320
  • [27] Pretreatment with Panaxatriol Saponin Attenuates Mitochondrial Apoptosis and Oxidative Stress to Facilitate Treatment of Myocardial Ischemia-Reperfusion Injury via the Regulation of Keap1/Nrf2 Activity
    Yao, Huan
    Xie, Qian
    He, Qingman
    Zeng, Lei
    Long, Jing
    Gong, Yuanyuan
    Li, Xueping
    Liu, Weiwei
    Xu, Zhiyi
    Wu, Huihui
    Zheng, Chuan
    Gao, Yongxiang
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
  • [28] Pretreatment with low-dose gadolinium chloride attenuates myocardial ischemia/reperfusion injury in rats
    Min Chen
    Yuan-yuan Zheng
    Yun-tao Song
    Jing-yi Xue
    Zheng-yang Liang
    Xin-xin Yan
    Da-li Luo
    Acta Pharmacologica Sinica, 2016, 37 : 453 - 462
  • [29] Queen bee acid pretreatment attenuates myocardial ischemia/ reperfusion injury by enhancing autophagic flux
    Chen, Changhai
    Ou, Wen
    Yang, Chaobo
    Liu, Haiqiong
    Yang, Tao
    Mo, Huaqiang
    Lu, Weizhe
    Yan, Jing
    Chen, Aihua
    HELIYON, 2024, 10 (12)
  • [30] Pretreatment with low-dose gadolinium chloride attenuates myocardial ischemia/reperfusion injury in rats
    Chen, Min
    Zheng, Yuan-yuan
    Song, Yun-tao
    Xue, Jing-yi
    Liang, Zheng-yang
    Yan, Xin-xin
    Luo, Da-li
    ACTA PHARMACOLOGICA SINICA, 2016, 37 (04) : 453 - 462